Heather J. Sutherland

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

Medicine, Oncology, Pharmacotherapy +14

Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

Robert Z. Orlowski, Arnon Nagler, Pieter Sonneveld et al. · Journal of Clinical Oncology · 2007 · 645 citations · Full text

Medicine, Oncology, Pharmacology +17

Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial

Suzanne Trudel, Nikoletta Lendvai, Rakesh Popat et al. · The Lancet Oncology · 2018 · 244 citations

Medicine, Oncology, Pharmacotherapy +16

Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Meletios Α. Dimopoulos, Jesús F. San Miguel, Andrew R. Belch et al. · Haematologica · 2018 · 210 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117)

Allison Blair, Heather J. Sutherland · Experimental Hematology · 2000 · 163 citations

Medicine, Cell Biology, Oncology +7